Blog
GLP-1 News & Updates
FDA updates, drug pricing news, insurance coverage changes, and the latest clinical trial results for GLP-1 weight loss medications.
FDA Sends 30 Warning Letters to Telehealth Companies Over Misleading GLP-1 Claims
The FDA cracked down on telehealth companies making false claims about compounded GLP-1 alternatives, sending 30 warning letters in its biggest enforcement action yet.
The DoseTrump Admin Delays Medicare GLP-1 Coverage After Insurers Balk at Program
The BALANCE Model for Medicare GLP-1 coverage is indefinitely postponed after failing to meet 80% insurer participation threshold, though Bridge program extends through 2027.
The DoseFDA Plans July Meeting to Ease Peptide Restrictions After RFK Jr. Push
RFK Jr.'s peptide advocacy leads FDA to schedule July meetings on lifting Biden-era restrictions for compounding pharmacies, potentially opening new wellness treatment access.
The DoseNovo's Oral Semaglutide First to Show Promise for Kids with Type 2 Diabetes
Novo Nordisk's PIONEER TEENS trial shows oral semaglutide reduced blood sugar by 0.83% in kids aged 10-17, potentially becoming the first oral GLP-1 for pediatric diabetes.
The DoseNovo Nordisk Files First-Ever Dual GLP-1/Amylin Drug for FDA Review
CagriSema combines semaglutide with a novel amylin receptor agonist, achieving 23% weight loss in trials and representing the first dual-mechanism GLP-1 therapy to seek approval.
The DoseFDA Sets New 'Four Prescription' Limit for Compounded GLP-1 Drugs
New FDA guidance restricts compounding pharmacies to just four monthly prescriptions of compounded GLP-1 copies, tightening access to affordable alternatives.
The DoseGLP-1 Pioneers Propose Radical Shift: Drop GLP-1 Entirely for Weight Loss
Researchers behind today's GLP-1 obesity drugs suggest targeting GLP-1 may not be necessary, proposing GIP/glucagon dual agonist that could match weight loss with fewer side effects.
The DoseLilly's Foundayo Sees Modest Launch with Just 1,390 Prescriptions in Debut Week
Eli Lilly's new oral GLP-1 pill Foundayo recorded only 1,390 prescriptions in its first week, a surprisingly modest start that contrasts sharply with Novo's oral Wegovy success.
The DoseFDA Requests Safety Studies for Foundayo Despite Recent Approval
Just days after approving Foundayo, the FDA is asking Eli Lilly for additional data on potential heart, liver, and thyroid cancer risks.
The DoseLilly Responds to FDA Safety Request with Foundayo Heart Trial Data
Eli Lilly released cardiovascular safety data for Foundayo just days after FDA demanded additional studies on potential heart and liver risks.
The DoseFoundayo Hits Pharmacies as FDA Demands Additional Safety Data From Eli Lilly
Eli Lilly's new oral GLP-1 pill Foundayo launched in US pharmacies this week, but the FDA is requiring new safety studies for cardiovascular risks and other concerns.
The DoseWhy 1 in 10 People May Be Genetically Resistant to GLP-1 Drugs Like Ozempic
New Stanford research reveals specific genetic variants in 10% of people cause 'GLP-1 resistance,' explaining why Ozempic and Wegovy work poorly for some users despite having higher hormone levels.